Biotech startup Daré partners with Rosy Wellness to bring new 'DARE to PLAY' sexual wellness cream to market
Rosy Wellness has 250,000 users and healthcare professional endorsement
A new collaboration between San Diego-based Daré Bioscience and digital health platform Rosy Wellness aims to address the long-neglected field of female sexual health, with the launch of a topical sildenafil cream – branded “DARE to PLAY” – set to hit the US market by prescription in the fourth quarter of 2025.
The cream, which makes use of sildenafil citrate (the active ingredient in Viagra®), has been reformulated as a topical compound intended to boost blood flow to genital tissues, supporting the physiological process of sexual arousal in women. As a Section 503B compounded drug, Daré expects to begin generating revenue once the product becomes available late next year.
Rosy Wellness, a female-focused health app with 250,000 users and endorsement from over 8,000 healthcare professionals, will lead digital outreach and educational efforts. The campaign — aimed at destigmatising female sexuality — will involve targeted engagement with both consumers and health‑care providers, alongside a supportive companion care platform.
“Female sexual health remains significantly underserved, and we believe our DARE to PLAY Sildenafil Cream represents a meaningful advancement,” said Sabrina Martucci Johnson, president and CEO of Daré Bioscience.
“Partnering with Rosy allows us to connect with women in a trusted, authentic space that encourages open discussion and education about sexual wellness.”
A key concern for women
The initiative addresses a gap in women’s health, with Daré pointing out that 65% of the Rosy community reported concerns around arousal when screened using the Female Sexual Function Index. The partnership aims not only to raise awareness but also to ensure users receive tailored support throughout their experience.
Lyndsey Harper, MD, founder and CEO of Rosy, commented:
“At Rosy, we’re committed to closing gaps in women’s healthcare with evidence-based, accessible solutions. This partnership with Daré accelerates our efforts to bring much needed attention and resources to sexual wellness, a historically stigmatized area. Together, we can expand sexual wellness education, access, and support for women.”
Daré Bioscience, a Nasdaq‑listed company focused on women’s health solutions, already markets the vaginal antibacterial gel XACIATO™ and is developing several other products, including a hormone‑free contraceptive ring and a compounded hormone‑therapy cream.